Diabetes research and clinical practice最新文献_第10页

Metabolic syndrome mediates the association between body roundness index and incident stroke risk in Chinese adults aged 45 years and older: Evidence from the CHARLS 代谢综合征介导45岁及以上中国成年人体圆度指数与卒中发生风险之间的关联：来自CHARLS的证据

IF 7.4 3区医学

Diabetes research and clinical practice Pub Date : 2026-01-01 Epub Date: 2025-12-10 DOI: 10.1016/j.diabres.2025.113050

Hongwei Liu , Gaiying Ma , Jing Shi , Minheng Zhang , Fei Xu , Miaomiao Hou

{"title":"Metabolic syndrome mediates the association between body roundness index and incident stroke risk in Chinese adults aged 45 years and older: Evidence from the CHARLS","authors":"Hongwei Liu , Gaiying Ma , Jing Shi , Minheng Zhang , Fei Xu , Miaomiao Hou","doi":"10.1016/j.diabres.2025.113050","DOIUrl":"10.1016/j.diabres.2025.113050","url":null,"abstract":"<div><h3>Background</h3><div>The body roundness index (BRI) has been identified as a new way to measure visceral fat, yet its relationship with stroke and how metabolic syndrome (MetS) affects this relationship are still ambiguous.</div></div><div><h3>Methods</h3><div>The investigation employed CHARLS cohort data for prospective analysis. To analyze the connection between BRI and stroke, Cox proportional hazards models and restricted cubic spline analysis were employed. The analysis of mediation assessed the role of MetS and its individual components. The discriminative effectiveness of BRI/other anthropometric measures was assessed using receiver operating characteristic (ROC) curves.</div></div><div><h3>Results</h3><div>The association continued to be significant among participants without MetS (HR = 2.50, 95 %CI: 1.69–3.67; p < 0.001), unlike those with MetS (HR = 0.97, 95 %CI: 0.43–2.18; p < 0.935). In ROC analysis, BRI outperformed traditional indices in stroke discrimination, particularly in those without MetS (AUC = 0.660 compared to 0.638 with MetS). Metabolic components explained about 22 % of the BRI-stroke association, with blood pressure contributing 11 %. Although statistically significant, this mediation was modest, and other components were not individually significant, suggesting a limited indirect effect that should be interpreted cautiously.</div></div><div><h3>Conclusion</h3><div>In metabolically healthy individuals, BRI shows a moderate predictive value for stroke, partly mediated by blood pressure.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"231 ","pages":"Article 113050"},"PeriodicalIF":7.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145733406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acute hypoglycemia attenuates serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in type 2 diabetes 急性低血糖降低2型糖尿病患者血清基质金属蛋白酶和金属蛋白酶组织抑制剂。

IF 7.4 3区医学

Diabetes research and clinical practice Pub Date : 2026-01-01 Epub Date: 2025-12-29 DOI: 10.1016/j.diabres.2025.113076

Abu Saleh Md Moin , Radwan Darwish , Thozhukat Sathyapalan , Stephen L. Atkin , Alexandra E. Butler

{"title":"Acute hypoglycemia attenuates serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in type 2 diabetes","authors":"Abu Saleh Md Moin , Radwan Darwish , Thozhukat Sathyapalan , Stephen L. Atkin , Alexandra E. Butler","doi":"10.1016/j.diabres.2025.113076","DOIUrl":"10.1016/j.diabres.2025.113076","url":null,"abstract":"<div><h3>Background</h3><div>Extracellular matrix (ECM) remodeling by matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) contributes to vascular complications in type 2 diabetes (T2D), but the impact of acute insulin-induced hypoglycemia on this axis is unclear.</div></div><div><h3>Objective</h3><div>Assess whether hypoglycemia alters circulating MMP/TIMP levels in T2D versus controls.</div></div><div><h3>Methods</h3><div>In a prospective study, 46 adults (23 T2D; 23 matched controls) underwent stepwise insulin to glucose ≤2.2 mmol/L. Eleven MMPs and three TIMPs were measured at baseline, during hypoglycemia, and up to 24 h post-recovery.</div></div><div><h3>Results</h3><div>At baseline, T2D had higher MMP1, MMP7, MMP9, and TIMP1/3. During hypoglycemia, controls showed a transient MMP1 rise with post-recovery decline. In T2D, MMP8 increased from 1–24 h and exceeded controls at 1–4 h. MMP2 fell early then rebounded at 4 h. MMP3 rose at 4 h in both groups and persisted to 24 h in T2D. MMP9 remained elevated in T2D, decreasing only at 24 h. TIMP3 declined during recovery in controls but stayed elevated in T2D; TIMP1/2 were unchanged.</div></div><div><h3>Conclusion</h3><div>Acute hypoglycemia induces subtype-specific, time-dependent MMP–TIMP shifts. T2D shows amplified, prolonged responses—especially MMP8, MMP3, and MMP9—with insufficient TIMP buffering, suggesting a proteolytic milieu that may impair ECM integrity and vascular stability.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"231 ","pages":"Article 113076"},"PeriodicalIF":7.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145877941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimal age, duration of diabetes and frequency of screening for diabetic nephropathy in children and youths with type 1 Diabetes: A systematic review 儿童和青少年1型糖尿病患者的最佳年龄、糖尿病病程和糖尿病肾病筛查频率：一项系统综述

IF 7.4 3区医学

Diabetes research and clinical practice Pub Date : 2026-01-01 Epub Date: 2025-12-08 DOI: 10.1016/j.diabres.2025.113042

Stefano Passanisi , Claudia Piona , Valentina Mancioppi , Louise Puli , Kim C. Donaghue

{"title":"Optimal age, duration of diabetes and frequency of screening for diabetic nephropathy in children and youths with type 1 Diabetes: A systematic review","authors":"Stefano Passanisi , Claudia Piona , Valentina Mancioppi , Louise Puli , Kim C. Donaghue","doi":"10.1016/j.diabres.2025.113042","DOIUrl":"10.1016/j.diabres.2025.113042","url":null,"abstract":"<div><div>Diabetic nephropathy (DN) is a major complication of type 1 diabetes (T1D) with lifelong health implications. This systematic review evaluated the optimal age, duration of diabetes, and frequency for DN screening in children and adolescents with T1D. A comprehensive literature search (1995–2024) across major databases identified 36 eligible studies, predominantly cross-sectional, encompassing 21,778 participants. Moderate albuminuria prevalence was 9.5 % overall, with most cases occurring after seven years of diabetes duration and in individuals older than 14 years, though rare cases were reported as early as 8.5 years and within two years of diagnosis. Severe albuminuria was less frequent (0.3–14.6 %), while end-stage kidney disease was rare, and no deaths were reported. Higher HbA1c levels (≥9%) were strongly associated with increased nephropathy risk, whereas limited data were available on blood pressure and other risk factors. No randomized trials or direct comparisons of screening strategies were identified, and heterogeneity in definitions and diagnostic methods limited evidence quality. Overall, findings support current international guidelines recommending screening from age 11 or puberty after 2–5 years of T1D duration, with intensified strategies potentially warranted for those with elevated HbA1 levels. High-quality, prospective studies are needed, especially in low- and middle-income countries.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"231 ","pages":"Article 113042"},"PeriodicalIF":7.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145721456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Kidney function decline mediates the adverse effects of arterial stiffness on all-cause and cardiovascular disease mortality in Cardiovascular-Kidney-Metabolic syndrome population: A cohort study 在心血管-肾脏-代谢综合征人群中，肾功能下降介导动脉僵硬对全因和心血管疾病死亡率的不良影响：一项队列研究

IF 7.4 3区医学

Diabetes research and clinical practice Pub Date : 2026-01-01 Epub Date: 2025-12-11 DOI: 10.1016/j.diabres.2025.113051

Song Liu , Qizhang Man , Shuan Wang , Yifeng Huang , Jinfeng Wen , Ying Yang , Hao Xie , Lei Fan

{"title":"Kidney function decline mediates the adverse effects of arterial stiffness on all-cause and cardiovascular disease mortality in Cardiovascular-Kidney-Metabolic syndrome population: A cohort study","authors":"Song Liu , Qizhang Man , Shuan Wang , Yifeng Huang , Jinfeng Wen , Ying Yang , Hao Xie , Lei Fan","doi":"10.1016/j.diabres.2025.113051","DOIUrl":"10.1016/j.diabres.2025.113051","url":null,"abstract":"<div><h3>Aids</h3><div>Cardiovascular-Kidney-Metabolic (CKM) syndrome links metabolic, renal, and cardiovascular disorders. The prognostic value and mechanisms of estimated pulse wave velocity (ePWV) in CKM syndrome remain unclear.</div></div><div><h3>Methods</h3><div>We analyzed 34,004 CKM syndrome patients from NHANES 1999–2018. Cox regression, restricted cubic splines, and mediation analyses examined ePWV-mortality associations and renal function’s mediating role.</div></div><div><h3>Results</h3><div>Over 104 months median follow-up, 4,141 all-cause and 1,261 cardiovascular deaths occurred. In fully adjusted model, each unit ePWV increase associated with 32 % higher all-cause mortality (HR: 1.32, 95 % CI: 1.29–1.35) and 34 % higher CVD mortality (HR: 1.34, 95 % CI: 1.28–1.40). The association showed L-shaped patterns in non-advanced CKM cases and linear relationships in advanced stages. Kidney function decline mediated 24 % of all-cause and 26 % of CVD mortality risk.</div><div>Conclusions.</div><div>Elevated ePWV predicts increased mortality in CKM syndrome patients, with kidney function decline as a significant mediating pathway. These findings highlight the importance of arterial stiffness assessment and renal protection in CKM management.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"231 ","pages":"Article 113051"},"PeriodicalIF":7.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145741535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Weight loss from glucagon-like peptide-1 receptor agonists by genetic factors in adults with type 2 diabetes 2型糖尿病成人患者胰高血糖素样肽-1受体激动剂所致体重减轻的遗传因素

IF 7.4 3区医学

Diabetes research and clinical practice Pub Date : 2026-01-01 Epub Date: 2025-12-03 DOI: 10.1016/j.diabres.2025.113041

Yulu Zheng , Zheng Guo , Eugene Jeong , Shuai Xu , Jason M. Samuels , Ghadeer K Dawwas , Ran Tao , Gitanjali Srivastava , You Chen , Danxia Yu

{"title":"Weight loss from glucagon-like peptide-1 receptor agonists by genetic factors in adults with type 2 diabetes","authors":"Yulu Zheng , Zheng Guo , Eugene Jeong , Shuai Xu , Jason M. Samuels , Ghadeer K Dawwas , Ran Tao , Gitanjali Srivastava , You Chen , Danxia Yu","doi":"10.1016/j.diabres.2025.113041","DOIUrl":"10.1016/j.diabres.2025.113041","url":null,"abstract":"<div><h3>Aims</h3><div>To identify whether genetic predisposition to obesity influences the weight loss effect of glucagon-like peptide-1 receptor agonists (GLP-1RAs) among adults with type 2 diabetes (T2D).</div></div><div><h3>Methods</h3><div>This study evaluated 52-week weight loss trajectories. Genetic exposures comprised: 1) a BMI polygenic risk score (PRS) incorporating 935,416 single-nucleotide polymorphisms (SNPs) and stratified into low (bottom 20 %), intermediate (middle 60 %), and high (top 20 %) categories; and 2) five major genetic variants for BMI PRS. Linear mixed models were applied to assess the associations between genetic factors and weight loss percentage, and the interaction effect between genetic factors and follow-up time was further considered.</div></div><div><h3>Results</h3><div>Among the 1,055 included adults (mean age 59 ± 11 years, 55 % female), intermediate and high BMI PRS groups were modestly associated with less weight loss over 52 weeks (0.7 % and 1.5 %, <em>P</em> = 0.0017 and 0.0023, respectively) than the low BMI PRS group. Individual SNPs showed no significant association with weight loss. BMI PRS modified response over time—intermediate PRS showed less early weight loss, whereas high PRS showed less late weight loss; several genotypes also showed significant time-varying effects.</div></div><div><h3>Conclusions</h3><div>BMI PRS could potentially be used to personalize obesity management with GLP-1RAs. Large-scale, multi-ancestry studies are needed to validate the application.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"231 ","pages":"Article 113041"},"PeriodicalIF":7.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145682021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Major adverse cardiovascular and limb events caused by tirzepatide in patients with type 2 diabetes at high cardiovascular risk: A comparison with sitagliptin 替西帕肽对高危2型糖尿病患者的主要心血管和肢体不良事件：与西格列汀的比较

IF 7.4 3区医学

Diabetes research and clinical practice Pub Date : 2026-01-01 Epub Date: 2025-12-23 DOI: 10.1016/j.diabres.2025.113072

Yoshihiro Iwasaki , Takenobu Shimada , Takefumi Kishimori , Takao Kato , Jumpei Koike , Takehiro Matsumoto , Takafumi Yagi , Masaharu Okada

{"title":"Major adverse cardiovascular and limb events caused by tirzepatide in patients with type 2 diabetes at high cardiovascular risk: A comparison with sitagliptin","authors":"Yoshihiro Iwasaki , Takenobu Shimada , Takefumi Kishimori , Takao Kato , Jumpei Koike , Takehiro Matsumoto , Takafumi Yagi , Masaharu Okada","doi":"10.1016/j.diabres.2025.113072","DOIUrl":"10.1016/j.diabres.2025.113072","url":null,"abstract":"<div><h3>Aims</h3><div>To elucidate the overall protective effects of tirzepatide against atherosclerosis-related events, including cardiovascular and lower-extremity events.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study using the TriNetX global health research network to identify patients with type 2 diabetes (T2D) who initiated tirzepatide or sitagliptin between January 2022 and December 2023. The primary outcome was major adverse cardiovascular and limb events (MACLE), defined as the composite of major adverse cardiovascular events (MACE: all-cause death, myocardial infarction, and stroke) and major adverse limb events (MALE: all-cause death and major lower extremity amputation). Propensity score matching was applied.</div></div><div><h3>Results</h3><div>After matching, 31,751 patients per group were analyzed. At 1 year, the incidence of MACLE was lower with tirzepatide compared to that with sitagliptin (4.3 % vs. 6.1 %; hazard ratio (HR), 0.70; 95 % confidence interval (CI), 0.66–0.76; p < 0.001). Tirzepatide was also associated with a reduced risk of MACE (HR, 0.71; 95 % CI, 0.66–0.76), MALE (HR, 0.39; 95 % CI, 0.34–0.46), and major lower extremity amputation (HR, 0.61; 95 % CI, 0.44–0.84). Consistent benefits were observed across major subgroups.</div></div><div><h3>Conclusions</h3><div>Tirzepatide was associated with a significantly lower risk of cardiovascular and limb events compared to sitagliptin in patients with T2D.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"231 ","pages":"Article 113072"},"PeriodicalIF":7.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145833304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Disease management, outcomes, and healthcare resource utilization in real-life clinical practice of diabetes and diabetic kidney disease in Finland 芬兰糖尿病和糖尿病肾病临床实践中的疾病管理、结果和医疗资源利用

IF 7.4 3区医学

Diabetes research and clinical practice Pub Date : 2026-01-01 Epub Date: 2025-12-21 DOI: 10.1016/j.diabres.2025.113067

Merja K. Laine , Mervi Haapala , Kristiina Uusi-Rauva , Juhani Aakko , Markku Pentikäinen , Kirsi Mikkola , Nami Halonen , Kari Pulkki , Niina Säävuori , Per-Henrik Groop , Kaj Metsärinne

{"title":"Disease management, outcomes, and healthcare resource utilization in real-life clinical practice of diabetes and diabetic kidney disease in Finland","authors":"Merja K. Laine , Mervi Haapala , Kristiina Uusi-Rauva , Juhani Aakko , Markku Pentikäinen , Kirsi Mikkola , Nami Halonen , Kari Pulkki , Niina Säävuori , Per-Henrik Groop , Kaj Metsärinne","doi":"10.1016/j.diabres.2025.113067","DOIUrl":"10.1016/j.diabres.2025.113067","url":null,"abstract":"<div><h3>Aims</h3><div>A significant number of individuals with diabetes have chronic kidney disease (CKD). Delays in diagnosis and management of CKD hinder treatment initiation and worsen outcomes. The adherence to monitoring and pharmacological treatments is poorly characterized worldwide.</div></div><div><h3>Methods</h3><div>We determined the prevalence, outcomes, treatment adherence, and healthcare resource utilization in individuals with type 1 (T1D) or type 2 (T2D) diabetes managed since 2008 in Finland. The management of CKD, glucose monitoring, and outcomes by SGLT-2 inhibitor (SGLT-2i) discontinuation were determined in large subpopulations.</div></div><div><h3>Results</h3><div>The prevalence of diabetes was 9.9 % in 2021. Despite having averaged 40–50 healthcare contacts per year, only one-third completed the recommended annual urine albumin-creatinine ratio (UACR) test. Factors positively associated with UACR test adherence included older age, male sex, T2D, higher HbA<sub>1c</sub> values, municipality, and calendar year. In T1D, 29 %, and in T2D, 75 % had HbA<sub>1c</sub> ≤ 53 mmol/mol. SGLT-2i was prescribed to 19 % of individuals with diabetes but one-third discontinued within a year, accompanied by a trend towards increased occurrence of kidney complications and heart failure.</div></div><div><h3>Conclusions</h3><div>Individuals with diabetes remain neglected for albuminuria screening, pharmacological management of complications, and also glycemic control in T1D, underlining an urgent need for improved awareness and risk management.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"231 ","pages":"Article 113067"},"PeriodicalIF":7.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145818148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of early healthcare visits on cardiovascular disease risk in people with newly screened diabetes: emulating a target trial using a large insurance database 早期医疗保健访问对新筛查糖尿病患者心血管疾病风险的影响：使用大型保险数据库模拟目标试验

IF 7.4 3区医学

Diabetes research and clinical practice Pub Date : 2026-01-01 Epub Date: 2025-11-23 DOI: 10.1016/j.diabres.2025.113020

Kiyomitsu Fukaguchi , Tomohiro Shinozaki , Zui C. Narita , Atsushi Goto

{"title":"Effect of early healthcare visits on cardiovascular disease risk in people with newly screened diabetes: emulating a target trial using a large insurance database","authors":"Kiyomitsu Fukaguchi , Tomohiro Shinozaki , Zui C. Narita , Atsushi Goto","doi":"10.1016/j.diabres.2025.113020","DOIUrl":"10.1016/j.diabres.2025.113020","url":null,"abstract":"<div><h3>Aims</h3><div>To determine whether healthcare visits within one year after diabetes identification lower 10-year cardiovascular disease (CVD) risk compared with no visits.</div></div><div><h3>Methods</h3><div>We emulated a target trial in the nationwide JMDC Claims Database (>12 million Japanese beneficiaries). Adults aged 40–74 years with newly identified diabetes (HbA1c ≥ 6.5 % [48 mmol/mol] or fasting glucose ≥126 mg/dL) during annual health checkups between 1 January 2005 and 31 March 2021 and no prior history of CVD were assigned to an early-visit group (≥1 outpatient visit within one year) or a no-visit group. Weighted pooled logistic regression estimated 10-year risk differences and risk ratios for a composite CVD outcome.</div></div><div><h3>Results</h3><div>Among 148,288 participants (mean age 53 years; 77 % men; 421,466 person-years), 1,741 CVD events occurred. Early visits were associated with a lower 10-year composite CVD risk compared to no visits (risk difference –3.4 percentage points [95 % CI –6.2 to –1.4]; risk ratio 0.73 [95 % CI 0.59 to 0.87]). Subgroup analyses confirmed consistent results across various characteristics.</div></div><div><h3>Conclusions</h3><div>Early healthcare visits within one year of diabetes identification were associated with a lower 10-year CVD risk. Health systems should facilitate early follow-up after screening to translate early detection into cardiovascular benefit.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"231 ","pages":"Article 113020"},"PeriodicalIF":7.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145602974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development and validation of prediction models for gestational diabetes mellitus in first-trimester pregnant women 早期妊娠妇女妊娠期糖尿病预测模型的建立与验证。

IF 7.4 3区医学

Diabetes research and clinical practice Pub Date : 2026-01-01 Epub Date: 2025-12-16 DOI: 10.1016/j.diabres.2025.113048

Xiaohang Liu , Fang Hu , Ruohua Yan , Ruixia Liu , Shaofei Su , Yaguang Peng , Xiaoxia Peng , Chenghong Yin

{"title":"Development and validation of prediction models for gestational diabetes mellitus in first-trimester pregnant women","authors":"Xiaohang Liu , Fang Hu , Ruohua Yan , Ruixia Liu , Shaofei Su , Yaguang Peng , Xiaoxia Peng , Chenghong Yin","doi":"10.1016/j.diabres.2025.113048","DOIUrl":"10.1016/j.diabres.2025.113048","url":null,"abstract":"<div><h3>Aims</h3><div>Early intervention can reduce the risk of gestational diabetes mellitus (GDM) and related adverse pregnancy outcomes. Accordingly, this study aims to develop prediction models for GDM in early pregnant women.</div></div><div><h3>Methods</h3><div>Pregnant women enrolled at Beijing Obstetrics and Gynecology Hospital were included in the derivation and temporal datasets. Women with electronic data capture records from other subcenters were included in the external validation dataset. Logistic regression and eXtreme Gradient Boosting (XGBoost) models were used to predict the risk of GDM.</div></div><div><h3>Results</h3><div>A total of 20,435 pregnant women were included in the derivation dataset, with 1,997 pregnant women in the temporal validation dataset. Furthermore, 100 pregnant women were included in the external validation dataset. The logistic regression and XGBoost models demonstrated AUCs of 0.738 (95% CI: 0.707, 0.771) and 0.737 (95% CI: 0.706, 0.767) in temporal validation. For the external validation dataset, the AUCs were 0.674 (95% CI: 0.440, 0.879) and 0.737 (95% CI: 0.510, 0.929) for the logistic regression and XGBoost models, respectively.</div></div><div><h3>Conclusion</h3><div>Both the logistic regression and XGBoost models demonstrated satisfactory performance in the internal and temporal datasets. However, the XGBoost model showed more robust performance in the external validation dataset compared to the logistic regression model.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"231 ","pages":"Article 113048"},"PeriodicalIF":7.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145780466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

National and regional burden of early-onset type 2 diabetes mellitus in the Americas from 1990 to 2023, attributable to modifiable risk factors, and projections to 2050: a systematic analysis for the global burden of disease study 2023 1990年至2023年美洲早发性2型糖尿病的国家和区域负担，归因于可改变的风险因素，以及到2050年的预测：2023年全球疾病负担研究的系统分析

IF 7.4 3区医学

Diabetes research and clinical practice Pub Date : 2026-01-01 Epub Date: 2025-11-24 DOI: 10.1016/j.diabres.2025.113007

Zihao Liu , Xuanyi Li , Li Liang , Wei Cheng , Liying Zhao

{"title":"National and regional burden of early-onset type 2 diabetes mellitus in the Americas from 1990 to 2023, attributable to modifiable risk factors, and projections to 2050: a systematic analysis for the global burden of disease study 2023","authors":"Zihao Liu , Xuanyi Li , Li Liang , Wei Cheng , Liying Zhao","doi":"10.1016/j.diabres.2025.113007","DOIUrl":"10.1016/j.diabres.2025.113007","url":null,"abstract":"<div><h3>Aims</h3><div>This study aims to estimate the burden of early-onset type 2 diabetes mellitus (T2DM) attributable to modifiable risk factors (MRFs) in the Americas from 1990 to 2050.</div></div><div><h3>Methods</h3><div>We used data from the Global Burden of Disease Study 2023 to analyze mortality and disability-adjusted life years (DALYs) from early-onset T2DM due to MRFs in people aged 25–39 years. We calculated age-standardized rates, analyzed trends using Joinpoint regression, assessed health inequalities using the slope and concentration indices, and projected outcomes using a Bayesian age-period-cohort model.</div></div><div><h3>Results</h3><div>In 2023, Central Latin America recorded the highest age-standardized rates, while high-income regions reported the lowest rates. From 1990 to 2023, the age-standardized DALY rate exhibited an upward trend in Andean Latin America and High-income North America. Health inequality analysis revealed a slight concentration of the burden towards lower socioeconomic groups. Projections forecast a continued rise in absolute deaths and DALYs through 2050. Males consistently bore a higher burden than females across all regions.</div></div><div><h3>Conclusion</h3><div>Between 1990 and 2023, the burden of early-onset T2DM attributable to MRFs varied widely across the Americas, and, although health inequality improved in some regions, the overall burden is projected to increase through 2050.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"231 ","pages":"Article 113007"},"PeriodicalIF":7.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145616574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0